Oxford BioDynamics PLC (GB:OBD)
LSE:OBD
Want to see GB:OBD full AI Analyst Report?
OBD Stock Chart & Stats
0.24 p
0.04 p(3.63%)
At close: 4:00 PM EST
0.24 p
0.04 p(3.63%)
Day’s Range― - ―
52-Week Range0.15 p - 0.78 p
Previous CloseN/A
Volume22.58K
Average Volume (3M)21.87M
Market Cap
£7.08M
Enterprise Value7.45M
Total Cash (Recent Filing)£1.39M
Total Debt (Recent Filing)£5.11M
Price to Earnings (P/E)―
Beta-0.40
Next Earnings
Jan 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding4,290,911,000
10 Day Avg. Volume50,883,470
30 Day Avg. Volume21,870,725
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£1.80M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthReported revenue growth of 22.21% indicates improving commercial traction for EpiSwitch tests and services. Sustained top-line growth supports scale economics, strengthens bargaining power for partnerships, and helps absorb fixed lab, R&D and regulatory costs over coming quarters.
Diversified Revenue StreamsThe company generates revenue from commercial tests, fee-for-service EpiSwitch offerings, and potential licensing/partner payments. This multi-channel model reduces concentration risk, smooths revenue volatility and creates multiple pathways to monetize the core platform long-term.
Proprietary Platform MoatEpiSwitch’s proprietary 3D genomic conformation technology creates intellectual property and a platform advantage. Platform-led discovery and assay development enable repeatable services, potential licensing, and comparative differentiation that can sustain higher margins and partner lock-in over time.
Bears Say
High LeverageA debt-to-equity ratio of 4.58 shows heavy reliance on debt financing. High leverage limits financial flexibility, raises interest burdens and heightens refinancing risk, constraining the company’s ability to fund clinical validation or commercial expansion without dilutive or costly capital.
Negative ProfitabilityConsistent negative gross, EBIT and net margins (net margin -10.19%) indicate the business has not achieved sustainable unit economics. Without structural margin improvement, revenue growth will not translate into profitability, increasing dependence on external funding or strategic partners.
Weak Cash GenerationFree cash flow decline of -33.93% and negative operating cash flow highlight deteriorating cash generation. Persistent cash burn shortens runway, forces debt or equity raises, and elevates execution risk for R&D and commercial rollouts in the medium term.
Oxford BioDynamics News
OBD FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest share price was 0.15 p and its highest was 0.78 p in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Oxford BioDynamics PLC’s market cap is £7.08M.
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jan 26, 2027 which is in 219 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Currently, no data Available
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 4,290,911,000 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in GB:OBD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies. The company's key products encompass the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic tool for forecasting patient responses to checkpoint inhibitor immunotherapy; the EpiSwitch CST (Covid Severity Test), a sophisticated blood test designed to predict the severity of COVID-19 in adults; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome analysis and novel biomarker discovery. Established in 2007, Oxford BioDynamics Plc maintains its headquarters in Oxford, United Kingdom.
Technical Analysis
IXICO plc
―
SkinBioTherapeutics
―
Fusion Antibodies Plc
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---